With just over 100 days as CEO now under her belt, Catherine Owen Adams is looking to cruise rare disease-focused Acadia ...

TD Cowen analyst Ritu Baral maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) today and set a price target of $35.00.

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at ...

We recently published a list of 10 Firms End 2024 Stronger With Impressive Gains. In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other ...

Neuren Pharmaceuticals (ASX:NEU) has announced that its partner Acadia Pharmaceuticals has submitted a Marketing ...

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with ...

Brendan Teehan named Chief Commercial Officer and Krys Corbett named Chief Business Officer -- -- Key additions expected to ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $18.66, but opened at $18.25. ACADIA ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 10,720,000 ...

Neuren's partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment ...

Acadia Pharma seeks European marketing approval for trofinetide for the treatment of Rett syndrome: San Diego Thursday, January 16, 2025, 13:00 Hrs [IST] Acadia Pharmaceuticals In ...

In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against the other best medical stocks under $20. The medical industry plays a crucial role in ...